Short report: Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria

American Journal of Tropical Medicine and Hygiene

Volumn 83, Issue 4, 2010, Pages 873-875

  Creek, Darren ^a,b,e   Bigira, Victor ^c,e   Arinaitwe, Emmanuel ^c,e   Wanzira, Humphrey ^c,e   Kakuru, Abel ^c,e   Tappero, Jordan ^d,e   Kamya, Moses R ^c,e   Dorsey, Grant ^a,e   Sandison, Taylor G ^e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MONASH UNIVERSITY   (Australia)

^c INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUO COTECXIN; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; BENFLUMETOL; DIHYDROARTEMISININ; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PIPERAQUINE; QUINOLINE DERIVATIVE;

AGE; ANTIMICROBIAL THERAPY; ARTICLE; BREAST FEEDING; CONTROLLED STUDY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALARIA; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RURAL AREA; UGANDA; VOMITING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INFANT; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RISK;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; ETHANOLAMINES; FLUORENES; HUMANS; INFANT; MALARIA; QUINOLINES; RISK; UGANDA; VOMITING;

EID: 79958032686     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.10-0158     Document Type: Article

References (13)

1. Nosten F, White NJ, 2007. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77: 181-192.
2. Olliaro P, Wells TN, 2009. The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther 85: 584-595.
3. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, Kamya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G, 2009. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 49: 1629-1637.
4. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, 2007. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369: 757-765. (Pubitemid 46335820)
5. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H, 2008. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS ONE 3: e2390.
6. Zwang J, Ashley EA, Karema C, D'Alessandro U, Smithuis F, Dorsey G, Janssens B, Mayxay M, Newton P, Singhasivanon P, Stepniewska K, White NJ, Nosten F, 2009. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS ONE 4: e6358.
7. Leonardi E, Gilvary G, White NJ, Nosten F, 2001. Severe allergic reactions to oral artesunate: a report of two cases. Trans R Soc Trop Med Hyg 95: 182-183. (Pubitemid 34947383)
8. ter Kuile FO, Nosten F, Luxemburger C, Kyle D, Teja-Isavatharm P, Phaipun L, Price R, Chongsuphajaisiddhi T, White NJ, 1995. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ 73: 631-642.
9. Bukirwa H, Nayiga S, Lubanga R, Mwebaza N, Chandler C, Hopkins H, Talisuna AO, Staedke SG, 2008. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health 13: 1143-1152.
10. Price RN, Dorsey G, Nosten F, 2009. Antimalarial therapies in children from Papua New Guinea. N Engl J Med 360: 1254, author reply 1255.
11. Sim IK, Davis TM, Ilett KF, 2005. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother 49: 2407-2411. (Pubitemid 40734473)
12. Borrmann S, Sallas WM, Machevo S, Gonzalez R, Bjorkman A, Martensson A, Hamel M, Juma E, Peshu J, Ogutu B, Djimde A, D'Alessandro U, Marrast AC, Lefevre G, Kern SE, 2010. The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 15: 434-441.
13. ter Kuile FO, Luxemburger C, Nosten F, Thwai KL, Chongsuphajaisiddhi T, White NJ, 1995. Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 89: 660-664.